• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats.奥沙西泮对个体大鼠抗惊厥作用的药代动力学-药效学建模
Br J Pharmacol. 1990 Jan;99(1):53-8. doi: 10.1111/j.1476-5381.1990.tb14653.x.
2
Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure.以戊四氮阈浓度作为药效学指标,对大鼠中奥沙西泮抗惊厥反应进行药代动力学建模。
J Pharmacokinet Biopharm. 1988 Apr;16(2):203-28. doi: 10.1007/BF01062261.
3
Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats.奥沙西泮对衰老的BN/BiRij大鼠抗惊厥作用的药效学
Br J Pharmacol. 1992 Sep;107(1):165-70. doi: 10.1111/j.1476-5381.1992.tb14481.x.
4
Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat.在大鼠抗惊厥作用的直接皮层刺激模型中对几种抗癫痫药物的药效学特征进行研究。
J Pharmacol Exp Ther. 1994 May;269(2):521-8.
5
Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity.苯二氮䓬类药物脑电图效应的药代动力学-药效学建模。与受体结合及抗惊厥活性的相关性。
J Pharmacol Exp Ther. 1991 Apr;257(1):472-8.
6
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.苯妥英对大鼠抗惊厥及脑电图作用的药代动力学-药效学建模
J Pharmacol Exp Ther. 1998 Feb;284(2):460-6.
7
Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats.奥沙西泮在正常和肾功能不全大鼠中的单剂量药代动力学和药效学
Biol Pharm Bull. 1999 Jun;22(6):627-32. doi: 10.1248/bpb.22.627.
8
Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect.苯二氮䓬类药物在抗惊厥作用直接皮层刺激模型中的药代动力学/药效学关系
J Pharmacol Exp Ther. 1996 Nov;279(2):803-12.
9
Anticonvulsant pharmacodynamics and disposition of triazolam in rats.三唑仑在大鼠体内的抗惊厥药效学及处置情况
J Pharm Sci. 1996 Sep;85(9):999-1004. doi: 10.1021/js9503183.
10
Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.咪达唑仑对大鼠个体脑电图影响的药代动力学-药效学建模:给药速率和途径的影响
Br J Pharmacol. 1991 Mar;102(3):663-8. doi: 10.1111/j.1476-5381.1991.tb12230.x.

引用本文的文献

1
Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.苯二氮䓬类药物的药代动力学-药效学关系
Clin Pharmacokinet. 1996 Jan;30(1):52-76. doi: 10.2165/00003088-199630010-00004.
2
Increased sensitivity to the anticonvulsant effect of valproate in aging BN/BiRij rats.衰老的BN/BiRij大鼠对丙戊酸盐抗惊厥作用的敏感性增加。
Pharm Res. 1993 Jul;10(7):1046-51. doi: 10.1023/a:1018975025417.
3
Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.临床前研究中的药代动力学-药效学建模:原理与展望。
Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):41-7. doi: 10.1007/BF03220007.
4
Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats.奥沙西泮对衰老的BN/BiRij大鼠抗惊厥作用的药效学
Br J Pharmacol. 1992 Sep;107(1):165-70. doi: 10.1111/j.1476-5381.1992.tb14481.x.
5
Contributions of alpha 1-adrenoceptors, alpha 2-adrenoceptors and P2x-purinoceptors to neurotransmission in several rabbit isolated blood vessels: role of neuronal uptake and autofeedback.α1 -肾上腺素能受体、α2 -肾上腺素能受体和P2x -嘌呤受体对几只家兔离体血管神经传递的贡献:神经元摄取和自反馈的作用
Br J Pharmacol. 1992 Feb;105(2):347-54. doi: 10.1111/j.1476-5381.1992.tb14257.x.

本文引用的文献

1
Estrous and circadian periodicity and electroshock convulsions in rats.大鼠的发情周期、昼夜节律及电休克惊厥
Am J Physiol. 1962 Feb;202:379-82. doi: 10.1152/ajplegacy.1962.202.2.379.
2
Effect of brief restraint on the convulsive threshold of mice.短暂束缚对小鼠惊厥阈值的影响。
J Pharmacol Exp Ther. 1962 Dec;138:337-42.
3
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.理解剂量-效应关系:药代动力学-药效学模型的临床应用
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53. doi: 10.2165/00003088-198106060-00002.
4
Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.基于生理的药代动力学模型对大鼠和人体内地西泮处置的预测。
J Pharmacokinet Biopharm. 1983 Dec;11(6):577-93. doi: 10.1007/BF01059058.
5
ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.ELSMOS——一种用FORTRAN IV语言编写的扩展最小二乘建模系统,用于小型或微型计算机。
Comput Programs Biomed. 1984 Feb-Apr;18(1-2):43-9. doi: 10.1016/0010-468x(84)90022-9.
6
Plasma concentrations of clobazam and its N-desmethyl metabolite; protection against pentetrazol-induced convulsions in mice.氯巴占及其N-去甲基代谢物的血浆浓度;对小鼠戊四氮诱发惊厥的保护作用。
J Pharm Pharmacol. 1984 Sep;36(9):636-8. doi: 10.1111/j.2042-7158.1984.tb04917.x.
7
Anxiety.焦虑
Lancet. 1982 Nov 6;2(8306):1030-4. doi: 10.1016/s0140-6736(82)90059-9.
8
Kinetics of pharmacologic effects.药理效应动力学
Clin Pharmacol Ther. 1966 May-Jun;7(3):362-72. doi: 10.1002/cpt196673362.
9
Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.药理反应动力学。I. 完整动物和人体中反应与药物浓度之间的假定关系。
J Theor Biol. 1968 Aug;20(2):173-201. doi: 10.1016/0022-5193(68)90188-4.
10
Estimation of the blood-plasma concentration ratio of diazepam in the rat.大鼠体内地西泮血浆浓度比的测定。
J Pharmacokinet Biopharm. 1985 Jun;13(3):347-8. doi: 10.1007/BF01065659.

奥沙西泮对个体大鼠抗惊厥作用的药代动力学-药效学建模

Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats.

作者信息

Dingemanse J, Voskuyl R A, Langemeijer M W, Postel-Westra I, Breimer D D, Meinardi H, Danhof M

机构信息

Center for Bio-Pharmaceutical Sciences, University of Leiden, The Netherlands.

出版信息

Br J Pharmacol. 1990 Jan;99(1):53-8. doi: 10.1111/j.1476-5381.1990.tb14653.x.

DOI:10.1111/j.1476-5381.1990.tb14653.x
PMID:2331575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1917521/
Abstract
  1. The purpose of this investigation was to examine in vivo drug-concentration anticonvulsant effect relationships of oxazepam in individual rats following administration of a single dose. 2. Whole blood concentration vs time profiles of oxazepam were determined following administration of doses of 4, 8 and 12 mg kg-1. The pharmacokinetics could be described by an open 2-compartment pharmacokinetic model. Following 12 mg kg-1 the values (mean +/- s.e., n = 11) of clearance and volume of distribution were 28 +/- 2 ml min-1 kg-1 and 2.6 +/- 0.31 kg-1, respectively, and were not significantly different from the values obtained at the other doses. 3. The anticonvulsant effect was quantitated by a new technique which allows repetitive determination of the convulsive threshold by direct cortical stimulation within one rat. Significant dose-dependent elevations of the seizure threshold were observed. 4. By pharmacokinetic-pharmacodynamic modelling, a log-linear relationship was found between concentration and anticonvulsant effect. Following 12 mg kg-1 the values (mean +/- s.e., n = 11) of the pharmacodynamic parameters slope and minimal effective concentration (Cmin) were 243 +/- 27 microA and 0.11 +/- 0.02 mg l-1, respectively and not significantly different from the values obtained at the other doses. 5. In a repeatability study the pharmacodynamic parameters were determined twice on two different occasions with an interval of two weeks in the same group of 11 rats. The inter-animal variability in the pharmacodynamic parameter slope was 46%, whereas the intra-animal variability was 24 +/- 18%. The value of the minimal effective concentration was in each animal and on each occasion close to zero within the relatively narrow range of 0.01-0.30mgI. 6. The results of this study showed that it is possible to determine in vivo concentration-anticonvulsant effect relationships of oxazepam under non-steady-state conditions in individual rats. The anti-convulsant effect of oxazepam appeared to be a rapidly reversible direct effect and acute tolerance did not develop within the time frame of the experiments.
摘要
  1. 本研究的目的是在单剂量给药后,研究奥沙西泮在个体大鼠体内的药物浓度与抗惊厥作用的关系。2. 分别给予4、8和12mg/kg剂量的奥沙西泮后,测定了全血浓度随时间的变化曲线。其药代动力学可用开放二室药代动力学模型描述。给予12mg/kg剂量后,清除率和分布容积的值(平均值±标准误,n = 11)分别为28±2ml·min⁻¹·kg⁻¹和2.6±0.31kg⁻¹,与其他剂量所得值无显著差异。3. 采用一种新技术对惊厥阈值进行重复测定,该技术可通过直接皮层刺激在同一只大鼠体内定量抗惊厥作用。观察到惊厥阈值有显著的剂量依赖性升高。4. 通过药代动力学-药效学建模,发现浓度与抗惊厥作用之间呈对数线性关系。给予12mg/kg剂量后,药效学参数斜率和最小有效浓度(Cmin)的值(平均值±标准误,n = 11)分别为243±27μA和0.11±0.02mg/L,与其他剂量所得值无显著差异。5. 在一项重复性研究中,对同一组11只大鼠在两个不同时间间隔两周的情况下,两次测定药效学参数。药效学参数斜率的动物间变异性为46%,而动物内变异性为24±18%。在0.01 - 0.30mg/L相对较窄的范围内,每只动物每次的最小有效浓度值均接近零。6. 本研究结果表明,在个体大鼠的非稳态条件下,有可能确定奥沙西泮的体内浓度-抗惊厥作用关系。奥沙西泮的抗惊厥作用似乎是一种快速可逆的直接作用,并且在实验时间范围内未出现急性耐受性。